Biosimilars create
competition for change

The rising cost of treatment continues to remain
at the forefront of physician and patient concerns.

The need for UDENYCA®

Lack of competition enabled cost increases. Wholesale acquisition cost (WAC)
of Neulasta® (pegfilgrastim) has more than doubled since 2006.1

Biosimilars chart
Patients and payers share the cost burden
Although Centers for Medicare & Medicaid Services (CMS) and insurers have taken on a greater share of the increasing costs, patients also share in this cost burden through larger co-pay and co-insurance premiums. Increasing costs reduce access for patients who may have difficulties paying for supportive care.2
UDENYCA® offers a choice
Availability of a biosimilar introduces competition and helps control costs while delivering quality supportive care to patients who need it.3

for your practice4

Wholesale acquisition cost (WAC)*

UDENYCA® delivers high-quality treatment and the reliable outcomes you expect with Neulasta®, but with 33% cost savings per dose.*4-6

UDENYCA® reduced patient out-of-pocket (OOP)
costs by nearly 52% per dose7

Biosimilars chart2

* Based on WAC. WAC does not necessarily reflect actual prices paid by consumers, pharmacies, or third-party payers. UDENYCA® WAC of $4175 per prefilled syringe vs Neulasta® WAC of $6231 per prefilled syringe.

References: 1. US Bureau of Labor Statistics. Medi-Span Price Rx, 2018. 2. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;25(2):180-186. 3. Biosimilars overview. Biosimilars Forum. Accessed May 19, 2020. 4. First Databank, Inc. Pricing Compendia. 5. UDENYCA® (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2019. 6. Neulasta® (pegfilgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2020. 7. Data on file. Coherus BioSciences, Inc.; 2021.